




Resonance Health

Half Year Results FY26


Andrew Harrison, CEO
Benjamin Carruthers, CFO

Highlights

- ✓ 1H FY26 Revenue up 53% or \$2.8M to \$8.0M from 1H FY25
- ✓ 1H FY26 Normalised EBITDA of \$1.6M at 20% operating margin
- ✓ Profit after tax of \$1.5 million (1H FY25: \$1.0 million loss)
- ✓ Positive operating cashflow
- ✓ Major global pharma clinical trial execution progressing as planned
- ✓ TrialsWest clinic network expansion progressing ahead of expectations
- ✓ SaMD order and bid (but not awarded) pipeline now above \$10 million
- ✓ New Non-Invasive Liver Fibrosis medical device extended-proof-of-concept-trial (EPoC) completed subject enrolment
- ✓ New “Bridge” technology that automates and simplifies customer interaction has completed testing and validation with first customer deployment underway



Significant revenue growth and diversification with rapid scaling across 3 businesses...



Full Year FY26 Guidance

- ✓ FY23–FY26 strong revenue growth (~45% CAGR)
- ✓ Profitable ~\$2M EBITDA
- ✓ Diversified revenue
- ✓ Customer, clinical, and technical synergies

Rapid scaling across 3 businesses

We continue to significantly expand our addressable global market...



Data compiled from internal company market research



Resonance Clinical



New Imaging
Endpoints for
Metabolic & Obesity



VAT, SAT, MRE



The strategy of getting a greater “share of wallet” expands on 3 vector's, more *therapeutic areas*, more *services* to each customer, and more *customers* through organic (SaMD) or acquisitive (buy expertise & footprint) growth.



More sites – Geographic (Australia then overseas)

More phases – Later stage to Phase 1



Resonance Clinical

More services provided in-house



FerriScan®



CardiacT2*




HepaFatScan®

More devices and imaging endpoints

Other services



% \$ SPENDING IN GLOBAL CLINICAL TRIALS BY THERAPEUTIC AREA



Data compiled from internal company market research

Growth strategy continues to bear early fruit...

	<u>Therapeutic Area</u>	<u>Services</u>
Australian global pharma	Haematology	<i>First Liver / Spleen Iron, then Site services - TrialsWest</i>
US global pharma	Haematology	<i>First Liver / Spleen Iron, then central reading & image storage</i>
Top 10 Indian global pharma	Metabolic	<i>First CRO, then Site services – TrialsWest, & Liver fat & Stiffness</i>
Top 10 Indian global pharma	Obesity	<i>First Liver fat & VAT / SAT, then CRO & Site Services</i>
US Biotech	Oncology	CRO & Imaging Services
US Biotech	ENT	<i>First site services, then CRO Services</i>

Work Won

Opportunities

Strong Tailwinds

Australian Clinical Trial Market


Metric	2015	2019	2022	CAGR % (2019-22)
Expenditure	\$1.1 billion	\$1.4 billion	\$1.6 billion	4.1
Employment	6,900 employees	8,000 employees	7,700 employees	(1.5)
Patient participation	Not reported	95,000	90,000	(1.8)
Number of trials started	1,460	1,877	1,850	(0.5)
Share of global industry-sponsored trials	c.5%	c.5%	c.5%	N/A

Source: ANZCTR; Clinicaltrials.gov; L.E.K. research and analysis

Key Drivers - Australia

- ✓ Approvals and regulatory system
- ✓ Public private health system
- ✓ Multi-cultural population
- ✓ Population receptive to testing / participation
- ✓ R&D Tax incentives


Global Clinical Trial Market



Key Drivers - Globally


- ✓ Increasing rapidity of technological breakthroughs
- ✓ Shortening development timeframes
- ✓ Increase in outsourcing of trials
- ✓ Increase in efficiency of non-hospital trials

While oncology dominates the global trial landscape, there is rapid growth in other therapeutic areas...




In the metabolic diseases space rapid growth is being driven by GLP-1-like drugs

Glucagon-like peptide-1




CAGR Comparison: GLP-1 vs Other Endocrine Therapies (2025-2030)




Resonance's deep expertise in liver and related metabolic / obesity areas meets a significant opportunity...

GLP-1 Clinical Trial Volume (2020-2025)



GLP-1 Drug Market Size Growth (2020-2030)



Growth with financial discipline...

Entrenched profitability

- ✓ Build revenue base
- ✓ Disciplined cost control
- ✓ Business transformation providing strong financial base with significant growth potential

Generate strong FCF

- ✓ Operating cash flow positive
- ✓ Low sustaining capex
- ✓ Accretive expansion capex & acquisitions

Target EBITDA Margin Range ~ 25%

- ✓ Established overhead base that can be leveraged
- ✓ Revenue growth across three business segments, looking to drive margin uplift at full revenue scale
- ✓ Greater share of wallet reduces customer acquisition costs and increases margin capture / customer / project

Responsible growth

- ✓ Conservative gearing metrics - target Net Debt EBITDA < 2x (long term ~ 1.5x)
- ✓ Maintain a strong balance sheet – financial strength and greater flexibility to pursue attractive opportunities
- ✓ Properly support and embed new business streams and acquisitions

1HFY26 PROFIT & LOSS

- ✓ 53% revenue growth on pcp
- ✓ 20% normalised EBITDA margin, significant operating leverage driving margin accretion in future growth²
- ✓ Significant increase in NPAT to \$1.5M

Profit & Loss Summary ¹			
	1HFY26	1HFY25	%Change
Revenue \$M	8.0	5.2	+53%
Normalised EBITDA	1.6	(0.8)	
Normalised EBITDA Margin	20%	-14%	
Statutory NPBT	0.9	(1.5)	
Statutory NPAT	1.5	(1.0)	

¹ Abridged summary prepared for comparative purposes, refer to Annual Report for Statutory Accounts

² Normalised EBITDA = Statutory net profit – income tax – depreciation – amortisation – finance costs – share based payments

1HFY26 BALANCE SHEET

Balance Sheet Summary ¹		
\$M	1HFY26	1HFY25
Assets		
Cash & Equivalents	2.7	3.0
Trade debtors and other receivables	3.5	3.5
Intangibles	9.4	9.5
PPE and other assets	2.3	1.9
Liabilities		
Trade and other payables	(1.6)	(1.3)
Borrowings	(2.7)	(2.9)
Revenue received in advance	(0.9)	(3.2)
Other liabilities	(1.9)	(1.2)
Net Assets	10.9	9.4

- ✓ Strong net cash position \$2.7M
- ✓ \$2.7M debt facility

¹ Abridged summary prepared for comparative purposes, refer to Annual Report for Statutory Accounts

Business Outlook & Guidance

Resonance enters 2H FY26 with:

- ✓ Continued delivery under global major pharmaceutical agreements
- ✓ Record SaMD forward orders and bid-tender pipeline
- ✓ Expanding and increasingly profitable TrialsWest operations
- ✓ Near-term milestones in fibrosis SaMD development and workflow automation
- ✓ Previously stated guidance of full year FY26 Revenue of \$17M and EBITDA of \$2M is maintained.

Disclaimer Forward Looking Statements

This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health’s products and services.

These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.

This presentation does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, nor may it or any part of it form the basis of or be relied on in any connection with any contract or commitment. The information in this presentation does not take into account the objectives, financial situation or individual needs of any person. Nothing contained in this presentation constitutes investment, legal, tax, or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries and are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health would desire or require in reaching an investment decision.

To the maximum extent possible by law, none of Resonance Health, their officers, directors, employees, associates, or agents, nor any other person’s accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any error or omissions in it.



resonance-health-ltd/